The exact molecular mechanisms underlying the pathogenic role of TMPRSS2: ERG fusion in prostate cancer are yet to be fully uncovered, but there is evidence suggesting its association with the clinical course of the disease [3,6]. This evidence concerns the gene TMPRSS2 and prostate carcinoma.